Abstract
Pemphigus is the name of a group of life-threatening blistering diseases of the skin and mucous membranes. The base of treatment for this disease is corticosteroids; however, recently, new drugs, such as rituximab, have been verified for more severe forms of it.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mihais S, Sitru C. Immunopathology and molecular diagnosis of autoimmune bullous disease. J Cell Mol Med. 2007;11(3):462–81.
Sitaru C, Zillikens D. Mechanism of blister induction by autoantibodies. Exp Dermatol. 2005;14(12):861–7.
Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, et al. IgA pemphigus. Clin Dermol. 2011;29(4):437–42.
Kneisel A, Herti M. Autoimmune bullous skin disease. J Dtsch Dermatol Ges. 2011;9(10):844–56.
Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29(4):432–6.
James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29(3):405–12.
Brenner S, Wohl Y. A survey of sex differences in 249 pemphigus patients and possible explanations. Skin Med. 2007;6(4):163–5. 8.
Herbst A, Bystryn JC. Pattern of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42(3):422–7.
Amagai M. Ch 29. Pemphigus. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. vol 1. Elsevier; 2012. p. 461.
Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo- controlled trial. J Invest Dermatol. 2010;130(8):2041–8.
Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol. 2009;129(2):289–301.
Schmidt E, Goebeler M, Zillikens D. Rituximab in severe pemphigus. Ann N Y Acad Sci. 2009;1173:683–91.
Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus–an update. Eur J Dermatol. 2005;15(4):224–30.
Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology. 2009;218(3):237–45.
Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Mohammad Beigi, P.K. (2018). Clinical Research Introduction. In: A Clinician's Guide to Pemphigus Vulgaris. Springer, Cham. https://doi.org/10.1007/978-3-319-67759-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-67759-0_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67758-3
Online ISBN: 978-3-319-67759-0
eBook Packages: MedicineMedicine (R0)